News & Views

ASN 2012 – poster highlights in CKD-MBD

This year’s ASN Kidney Week featured over 150 posters on mineral bone disorders, covering topics such as FGF-23, the value of bone mineral density measurement, new therapeutic options and the potential impact of the US Prospective Payment System, or “bundle” reimbursement policy. Beneath, we review a selection of these posters…

Read more

Date of publication:
December 3, 2012

News & Views

ASN 2012 – towards “restoring patient health in a meaningful way”

The overarching theme of ASN Kidney Week 2012 was the push towards a “cure for kidney disease” or, as this was alternatively described, a drive towards “restoring patient health in a meaningful way”.  The plenaries in particular highlighted the importance of these goals, but the difficulties inherent in delivering transformational…

Read more

Date of publication:
November 28, 2012

News & Views

Calcium balance in the CKD population

To make an accurate assessment of the need for calcium supplementation in a CKD patient, a nephrologist needs a good understanding of the patient’s pre-supplementation calcium balance. In this article we review recent evidence by Spiegel and Brady [1] on this topic along with associated commentary. The Spiegel and Brady…

Read more

Date of publication:
November 8, 2012

News & Views

ASN Kidney Week 2012 Preview – five abstracts that caught our eye…

Kidney Week 2012 starts this week in San Diego. The annual meeting, organized by the American Society of Nephrology (ASN), is traditionally the largest global event for nephrologists and this year promises to continue this trend with over 3,400 posters and 400+ oral abstracts scheduled for presentation. We’ve been looking…

Read more

Date of publication:
October 29, 2012

News & Views

Is there value in measuring Bone Mineral Density in elderly CKD patients?

In our last post we reviewed how patients with CKD 3-5D have an increased risk of fracture compared with the general population, but that analysis into the relationship between CKD and Bone Mineral Density (BMD) has shown mixed results. In this follow-up article we continue our focus on the value…

Read more
Professor Stuart M. Sprague
Expert article by:
Professor Stuart M. Sprague

Date of publication:
October 15, 2012

News & Views

The value of measuring Bone Mineral Density in CKD non-dialysis & dialysis patients

The current Kidney Disease: Improving Global Outcomes (KDIGO) [1] guidelines state: “In patients with CKD stages 3-5D with evidence of CKD-MBD, we suggest that Bone Mineral Density (BMD) testing not be performed routinely, because BMD does not predict fracture risk as it does in the general population, and BMD does…

Read more
Professor Stuart M. Sprague
Expert article by:
Professor Stuart M. Sprague

Date of publication:
October 2, 2012

News & Views

Possible therapeutic strategies to lower FGF-23

Twelve years after the discovery of the hormone FGF-23 (fibroblast growth factor 23), many therapeutic options for targeting FGF-23 levels are emerging. Myles Wolf’s latest review paper [1] addresses the pertinent question as to whether CKD treatment regimens should now be tailored to address FGF-23 levels in addition to those…

Read more

Date of publication:
September 7, 2012

News & Views

Will FGF-23 become a critical marker in CKD management?

Welcome to our third instalment in our FGF-23 series exploring this potential marker and therapeutic target for chronic kidney disease. The position of FGF-23 as a biomarker of bone metabolism is progressing steadily. Last year, Isakova’s seminal study [1] reported that circulating FGF-23 concentrations were an independent predictor of progression…

Read more

Date of publication:
August 24, 2012

News & Views

Can FGF-23 predict clinical outcomes in CKD?

Numerous reports have linked elevated FGF-23 levels to the main adverse clinical outcomes in CKD: progression to end-stage renal disease (ESRD), cardiovascular disease, and death. Cross-sectional studies have also shown that increased FGF-23 levels in patients with CKD are associated with adverse systemic effects, increased mortality and deterioration of renal…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
August 13, 2012

News & Views

The clinical significance of FGF-23 in CKD

A proliferation of studies linking excess levels of the endocrine hormone fibroblast growth factor 23 (FGF-23) to adverse renal and cardiovascular outcomes in patients with Chronic Kidney Disease (CKD) is setting the stage for new clinical trials, which could lead to FGF-23 becoming an important marker and/or therapeutic target in…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
July 30, 2012

News & Views

CompAct Survey results of the ERA-EDTA 2012

The CompAct Survey started in November 2011 at the ASN congress in Philadelphia. Now the survey was conducted at the ERA-EDTA congress in Paris in May 2012. At this occasion 86 healthcare professionals participated and the overall results so far have been analyzed: In general, the survey results correspond to…

Read more

Date of publication:
July 23, 2012

Login

You are about to leave Compact-Renal.com

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel